Case todayBrokenLate SEC filing · Nov 17, 2026The case · mixed · Nov 17, 2026Own AAQL if AAQL is a highly speculative pivot story: the business case depends on whether a tiny, loss-making former online platform operator can turn Dao Ling Doctor health products and therapy services into a scalable, higher-margin.4 conditions1 strengthening · 1 holding · 2 weakeningNext resultsNot scheduledNo date filed yet

AAQL at a glance

The past year

Chart

+173.6% $1.57, close Nov 16

From the highest close
−2.1%
Vs the 200-day average
+133.6%
Nov 14, 2025Daily close, Antiaging Quantum LivingNov 16, 2026

Short interest

History

210 shares

Since the last report
+100.0%
Days to cover
1.0 day
Settled
Aug 29, 2025

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 12 – Nov 18

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

AAQL price history

Latest price$1.80Today+$0.23 (+14.94%)
AAQL +76.47%S&P 500 -4.96%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • The strategic pivot works only if Dao Ling Doctor-related therapy services and proprietary health/beauty products become the primary demand engine after the company exits its historical online platform support business.HoldingMateriality: High

    FY2026 GAAP annual revenue was $1,034,385, up 26.47% from FY2025, according to MD&A. If the new lines do not replace the legacy platform revenue, the company loses the base needed to support its overhead and the equity story becomes a financing exercise rather than an operating turnaround.

    Watch: Customers or distributors fail to adopt the Dao Ling Doctor proprietary products after the legacy support services are discontinued.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2026 GAAP annual revenue was $1,034,385, up 26.47% from FY2025, according to MD&A.

    Open source ↗
  • The proprietary product and therapy-service mix must preserve a structurally better gross-profit profile than the labor-intensive technical support model it is replacing.StrengtheningMateriality: High

    FY2026 GAAP annual gross profit rose to $702,123 from $428,517 in FY2025. A higher-margin mix is the main operating reason to believe the pivot can eventually fund the cost base; if it fades, growth would not solve the profitability problem.

    Watch: Health/beauty products require distributor discounts, returns, promotions or inventory markdowns that compress product margins.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2026 GAAP annual gross profit rose to $702,123 from $428,517 in FY2025.

    Open source ↗
  • The pivot must create operating leverage, because AAQL’s rent, facility, wage, legal and professional cost base is currently too large for its revenue scale.WeakeningMateriality: Medium

    FY2026 GAAP annual operating income was a loss of $835,401, worse than the FY2025 operating loss of $789,959. If revenue growth continues to require equal or greater SG&A growth, shareholders will not capture the gross-margin improvement as earnings or cash flow.

    Watch: Facility expansion produces therapy traffic and product sales without a matching increase in rent and staffing.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2026 GAAP annual operating income was a loss of $835,401, worse than the FY2025 operating loss of $789,959.

    Open source ↗
  • AAQL’s balance-sheet weakness and expanded share authorization make financing risk a core constraint on per-share value unless the operating pivot quickly reduces cash burn.WeakeningMateriality: Medium

    Stockholders’ equity was negative $675,871 at March 31, 2026. Even if the business grows, owners can lose if the growth is financed through heavy dilution or balance-sheet stress.

    Watch: AAQL obtains non-dilutive financing or liability settlements that materially improve the capital structure.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Stockholders’ equity was negative $675,871 at March 31, 2026.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

The strategic pivot works only if Dao Ling Doctor-related therapy services and proprietary health/beauty products become the primary demand engine after the company exits its historical online platform support business. If the new lines do not replace the legacy platform revenue, the company loses the base needed to support its overhead and the equity story becomes a financing exercise rather than an operating turnaround.

The proprietary product and therapy-service mix must preserve a structurally better gross-profit profile than the labor-intensive technical support model it is replacing. A higher-margin mix is the main operating reason to believe the pivot can eventually fund the cost base; if it fades, growth would not solve the profitability problem.

The pivot must create operating leverage, because AAQL’s rent, facility, wage, legal and professional cost base is currently too large for its revenue scale. If revenue growth continues to require equal or greater SG&A growth, shareholders will not capture the gross-margin improvement as earnings or cash flow.

AAQL’s balance-sheet weakness and expanded share authorization make financing risk a core constraint on per-share value unless the operating pivot quickly reduces cash burn. Even if the business grows, owners can lose if the growth is financed through heavy dilution or balance-sheet stress.

All standing thesis claims
Original report summary

AAQL is a highly speculative pivot story: the business case depends on whether a tiny, loss-making former online platform operator can turn Dao Ling Doctor health products and therapy services into a scalable, higher-margin.

Evidence assessed Nov 17, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Antiaging Quantum Living

Where the evidence on Antiaging Quantum Living disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 4 thesis points, 1 strengthening, 1 holding and 2 weakening.

Bull case: what the evidence supports

  • The strategic pivot works only if Dao Ling Doctor-related therapy services and proprietary health/beauty products become the primary demand engine after the company exits its historical online platform support business.

    sec.gov ↗

  • The proprietary product and therapy-service mix must preserve a structurally better gross-profit profile than the labor-intensive technical support model it is replacing.

    sec.gov ↗

Bear case: what the evidence questions

  • The pivot must create operating leverage, because AAQL’s rent, facility, wage, legal and professional cost base is currently too large for its revenue scale.

    sec.gov ↗

  • AAQL’s balance-sheet weakness and expanded share authorization make financing risk a core constraint on per-share value unless the operating pivot quickly reduces cash burn.

    sec.gov ↗

Thesis-Break Engine

What has broken in Antiaging Quantum Living’s thesis

Each break OptimistFi flagged on Antiaging Quantum Living, dated — with what has historically followed the same kind of break across the market, not a forecast for Antiaging Quantum Living.

peers+16%-43%-12%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -12% path vs comparable companies over six months, inside the middle-half range (+16% to -43%). A base rate, not a forecast.
  • Late SEC filingcondition set before this filing

    Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

No assessed change was returned in this research window. That can reflect a quiet period or a coverage limit.

Risks / falsifiers

What could break the thesis

  • Customers or distributors fail to adopt the Dao Ling Doctor proprietary products after the legacy support services are discontinued.
  • Health/beauty products require distributor discounts, returns, promotions or inventory markdowns that compress product margins.
  • Facility expansion produces therapy traffic and product sales without a matching increase in rent and staffing.
  • AAQL obtains non-dilutive financing or liability settlements that materially improve the capital structure.

AAQL news

Loading headlines…

Financial statements

AAQL income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

AAQL: quick answers

What is AAQL's short interest?
As of August 29, 2025, 210 AAQL shares were sold short, up 100.0% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. AAQL short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.